MeSH D001321 - autistic disorder
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D000067877:Autism spectrum disorder
0 Companies
0 Drugs
Success rate
D001321:Â
Autistic disorder
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Risperidone | Uzedy | 2025-01-12 | 2023-04-28 |  |  |
| Risperidone | Risperidone |  | 2023-12-05 |  |  | |
| Taro Pharmaceutical | Risperidone | Risperidone |  | 2011-02-07 |  |  |
| Johnson & Johnson | Risperidone | Risperdal |  | 1993-12-29 | $374 M | Y2022 |
| Sandoz | Risperidone | Risperidone |  | 2009-12-22 |  |  |
1
2
3
4
5
6
7
>
Clinical Trials
Historical Success Rate
Phase 1
40%6/15
Phase 2
57%26/46
Phase 3
34%12/35
Approved: 5Overall Success rate: 8%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
5
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use